A practical approach to the cholesterol guidelines and ASCVD prevention

Area of Science:

• Cardiology
• Preventive Medicine
• Public Health

Background:

• Lifestyle factors are fundamental to preventing atherosclerotic cardiovascular disease (ASCVD).
• Statins are the primary treatment for both primary and secondary ASCVD prevention.
• Physicians should counsel patients on statin risks and benefits.

Purpose of the Study:

• To review current guidelines for ASCVD prevention.
• To highlight the role of statins and non-statin therapies.
• To emphasize the importance of updated risk stratification methods.

Main Methods:

• Review of current clinical practice guidelines for ASCVD prevention.
• Analysis of the role of statins, non-statins, and PCSK9 inhibitors.
• Inclusion of emerging risk-enhancing factors in ASCVD risk assessment.

Main Results:

• Statins are first-line therapy for ASCVD prevention.
• Non-statins and PCSK9 inhibitors are recommended for secondary prevention in patients with established ASCVD.
• Chronic inflammatory conditions and ethnicity are identified as important risk-enhancing factors for intermediate-risk patients.

Conclusions:

• Lifestyle modifications and statin therapy are cornerstones of ASCVD prevention.
• Personalized risk assessment, incorporating new factors, is crucial for effective ASCVD prevention strategies.
• Shared decision-making regarding statin therapy is essential for patient adherence and outcomes.